- Wednesday, October 16, 2024
GSK PLC (GSK) has announced a collaboration with Chinese biopharma company Hansoh Pharma to license an antibody-drug conjugate (ADC) called HS-20093. Under the terms of the deal, GSK will pay $185 million upfront and up to $1.525 billion in success-based milestone payments.
HS-20093 has demonstrated promising potential for the treatment of lung cancer in early studies. ADCs are an innovative approach that specifically target cancer cells while minimizing damage to healthy cells. This therapeutic strategy has sparked numerous licensing agreements and collaborations within the pharmaceutical industry.
Previously, GSK and Hansoh collaborated on an ADC focused on ovarian and endometrial cancer. Similarly, AbbVie recently announced its acquisition of ImmunoGen Inc., which boasts an ADC for ovarian cancer as its key asset.
GSK plans to conduct phase 1 trials for HS-20093 outside of China starting in 2024. This development marks a significant step forward in the battle against lung cancer.
GSK's American depositary receipts experienced a 0.2% premarket increase and have soared by 3.9% year-to-date, while the S&P 500 has seen a 24% increase.
All Rights Reserved © 2024
Post a comment